A new study has determined that a novel enzyme in sperm is essential for sperm motility and male fertility. The research may offer a potential target for an effective, non-hormonal male contraceptive, the researchers said. Sperm motility, produced by the coordinated movement of the extremely long sperm tail, requires substantial energy in the form of adenosine triphosphate, or ATP, the major energy currency of the cell.
From University of North Carolina at Chapel Hill :
Sperm enzyme is essential for male fertility, study shows
Findings may have implications for contraceptive
A study led by scientists at the University of North Carolina at Chapel Hill has determined that a novel enzyme in sperm is essential for sperm motility and male fertility.
The new study may offer a potential target for an effective, non-hormonal male contraceptive, the researchers said. The findings will be published today (Nov. 15) in the online early edition of the journal Proceedings of the National Academy of Sciences. A report also will appear Nov. 23 in the journal’s print edition.
Collaborating with UNC were scientists from the U.S. National Institute of Environmental Health Sciences (NIEHS); Fudan University in Shanghai, China; and the U.S. Environmental Protection Agency.
Sperm motility, produced by the coordinated movement of the extremely long sperm tail, requires substantial energy in the form of adenosine triphosphate, or ATP, the major energy currency of the cell.
Specialized cellular structures known as mitochondria were thought to provide a substantial portion of the ATP needed for sperm motility. In contrast, Dr. Deborah A. O’Brien, associate professor of cell and developmental biology at UNC’s School of Medicine, and her colleagues found that sperm motility and ATP production depend primarily on a metabolic pathway known as glycolysis. This pathway uses sugar to produce energy, a common process in animal and plant cells.
The researchers focused on the enzyme glyceraldehyde 3-phosphate dehydrogenase-S, or GAPDS, a novel enzyme in the glycolytic pathway that is expressed only in germ cells very late in the process of sperm production.
GAPDS is tightly bound to a structural element that extends along most of the length of the sperm tail. The study team used gene targeting, or gene knockout technology, to produce mice that could not make this unique enzyme.
Without GAPDS, glycolysis is selectively blocked in sperm and this pathway produces no ATP. As expected, the females were normal and the males had normal testes and sperm counts, but they were infertile, O’Brien said.
And when the researchers analyzed sperm movement under a microscope, they found a surprise.
”We expected that a type of motility known as ‘hyperactivated motility’ would be inhibited, but found that all progressive movement was absent in sperm without GAPDS,” O’Brien said.
”Glycolysis may not be as efficient as mitochondria for producing energy, but the enzymes are abundant and in the right place for quick, localized energy production along the sperm tail. This paper provides proof of principle that GAPDS may be an effective target for a contraceptive agent.”
Co-authors with O’Brien are Dr. Kiyoshi Miki, research assistant professor in cell and developmental biology; Dr. Weidong Qu, postdoctoral researcher at UNC and associate professor at Fudan University; Eugenia Goulding and William Willis, research technicians at the NIEHS; Dr. Donna Bunch, assistant professor of medicine at UNC; Lillian Strader, research technician at the EPA; Dr. Sally Perreault, chief, gamete and early embryo biology branch at the EPA; and Dr. Edward M. Eddy, who heads the gamete biology section at the NIEHS.